Clinical trials: CRC, Colorectal Cancer
Colorectal Neoplasms
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan.
- Trial name
- NCT00361842
- Testing
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Where
- 13 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
- Trial name
- CheckMate 9X8 (NCT03414983)
- Testing
- Nivolumab, Oxaliplatin, Leucovorin
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT03992456
- Testing
- Panitumumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer, Neoplasm Metastasis
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic…
- Trial name
- NCT00444678
- Testing
- Cetuximab, Oxaliplatin, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Metastatic Colorectal Cancer
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard…
- Trial name
- 379 (NCT03791398)
- Testing
- Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Brown University
Recurrent Colon Cancer, Recurrent Rectal Cancer
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer
- Trial name
- NCT00103311
- Testing
- ispinesib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.
- Trial name
- NCT00191984
- Testing
- pemetrexed, irinotecan
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Eli Lilly and Company
Colon Cancer, Rectal Cancer
Prevention of Colorectal Cancer Through Multiomics Blood Testing
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a…
- Conditions
- Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases
- Trial name
- PREEMPT CRC (NCT04369053)
- Testing
- Freenome test
- Where
- 148 sites in United States, Canada
- Volunteers
- 48,995 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Colorectal Cancer
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00022698
- Testing
- Capecitabine, Irinotecan
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.
- Conditions
- Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
- Trial name
- CATIQ (NCT02195232)
- Testing
- Isoquercetin
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- Jeffrey Zwicker, MD
Previously Untreated Metastatic Colorectal Cancer
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic…
- Trial name
- FUTURE (NCT00439517)
- Testing
- UFOX + Cetuximab, FOLFOX4 + Cetuximab
- Where
- 57 sites in Argentina, Australia and 12 more
- Volunteers
- 302 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with…
- Trial name
- NCT00642603
- Testing
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin
- Where
- 76 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
Nausea and Vomiting, Chemotherapy-Induced
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of…
- Trial name
- NCT00601172
- Testing
- Casopitant, Dexamethasone, Ondansetron
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 710 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Purpose: The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with liver lesions from…
- Trial name
- NCT02015754
- Testing
- DEBIRI, LC Bead M1, TACE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Colorectal Adenoma, Colorectal Cancer
PRevention Using EPA Against coloREctal Cancer
This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma.
- Conditions
- Colorectal Adenoma, Colorectal Cancer, Endoscopic Surgery, Eicosapentaenoic Acid
- Trial name
- PREPARE (NCT04216251)
- Testing
- AMR101
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).
- Trial name
- POLAR-A (NCT04034355)
- Testing
- Calmangafodipir (5 µmol/kg)
- Where
- 65 sites in Belgium, Czechia and 8 more
- Volunteers
- 301 people
- Sponsor
- Egetis Therapeutics AB (publ)